Bexson Biomedical, Inc., a US-based biopharmaceutical company, announced on Tuesday that it has added Robert S Langer ScD to its Scientific Advisory Board (SAB).
Dr Langer serves as the David H. Koch Institute professor at MIT. He has served as both a member and chairman of the United States Food and Drug Administration's Science Board. He is the co-founder of Moderna.
Gregg Peterson, Bexson CEO, said, 'We are excited to have Dr Langer join our Scientific Advisory Board as a world leader in new biotechnology advancements and inventions who understands the complexities of the regulatory pathway for such advancements given his service as chairman of the FDA Science Board. Furthermore, we believe his addition to our SAB is a testament for our formulation technology, SEVALENT's, potential to disrupt the small molecule injectable market, bringing traditionally expensive, clinically delivered therapies, to the patients' home.'
Caliway Biopharmaceuticals commences CBL-0204 Phase 2b study patient recruitment
Adiso Therapeutics completes Phase 1b multiple ascending dose clinical trial assessing ADS051
Pfizer receives FDA approval for RSV vaccine in older adults
Establishment Labs Receives CE Mark Approval for Minimally Invasive Surgical Tools
Lexicon Pharma's drug for heart failure gains US FDA approval
EU regulator looking to revoke Novartis' sickle cell drug marketing authorisation
Ipsen Pharma receives negative CHMP opinion for palovarotene as potential FOP treatment
CHMP recommends extending use of Veklury for COVID-19 in severe renal impairment
Endo Ventures announces bivalirudin injection US distribution agreement with MAIA Pharmaceuticals
AgonOx and Providence Cancer Institute announce PH-762 collaborative clinical trial initiation